Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GS-9451

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We… Expand
  • table 1
  • table 2
  • figure 3
Is this relevant?
2015
2015
AbstractBackground As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2015
2015
BACKGROUND Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
Dietrich D et al., 2014 Mixed Multicenter Yes 276 Mean 59 181 (57) 145 (45) Modi AA et al., 2014 Community Multicenter Yes 32… Expand
Is this relevant?
2014
2014
GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
The discovery of GS-9451 is reported. Modification of the P3 cap and P2 quinoline with a series of solubilizing groups led to the… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Is this relevant?
2012
2012
GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected… Expand
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
The high genetic variation of hepatitis C virus (HCV) results in rapid selection of drug resistance mutations (DRMs) during… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?